Acute inpatient rehabilitation after left ventricular assist device implantation for congestive heart failure.
نویسندگان
چکیده
Heart failure affects an estimated 5.7 million Americans, and almost 300,000 people die from heart failure in the United States each year [1]. Patients with end-stage heart failure become severely disabled because of dyspnea at rest or with minimal exertion, despite maximal medical therapy. Symptoms that typify heart failure, including shortness of breath and fatigue, also have been shown to be directly related to abnormalities of skeletal muscle [2]. Present available treatment options for these patients include medications, cardiac transplantation, or placement of a left ventricular assist device (LVAD). An LVAD is a mechanical device that is used to partially or completely replace the function of the left ventricle. It may be used either for a short period before cardiac transplantation as a “bridging therapy” or for a long-term period as a “destination therapy” in patients who are too sick to undergo cardiac transplantation. Long-term use of an LVAD can result in a clinically meaningful survival benefit and an improved quality of life [3]. In general, patients who have undergone placement of an LVAD and are transferred to a rehabilitation unit have significant comorbidities and are severely deconditioned. Although LVAD placement improves cardiac hemodynamics, an immediate impact on the functional ability of the patient does not occur because of an associated skeletal myopathy. Rehabilitation for these patients is therefore important and challenging. We present our experience with 3 patients who underwent LVAD implantation as a destination therapy and then were admitted for acute inpatient rehabilitation.
منابع مشابه
Fluoroscopy-Guided Resolution of Ingested Thrombus Leading to Functional Disturbance of a Continuous-Flow Left Ventricular Assist Device
The third generation of left ventricular assist devices (LVADs) has been shown to improve outcome and quality of life in patients suffering from acute and chronic heart failure. However, VAD-associated complications are still a challenge in the clinical practice. Here we report the resolution of a mobile thrombus formation in the proximity of the inflow cannula of a third generation of LVADs (H...
متن کاملMinimally invasive approach for percutaneous CentriMag right ventricular assist device support using a single PROTEKDuo Cannula
BACKGROUND Right ventricular failure is a serious complication after left ventricular assist device placement. CASE PRESENTATION A 70-year-old male in decompensated heart failure with right ventricular failure after the placement of a left ventricular assist device. A single dual-lumen PROTEKDuo cannula was inserted percutaneously via the internal jugular vein to draw blood from the right atr...
متن کاملAmbulatory care of patients with left ventricular assist devices.
BACKGROUND Left ventricular assist devices (LVAD) have revolutionized the treatment of patients with acute and chronic heart failure as they provide a high quality of life. We report on our experience with patients receiving ambulatory care after LVAD implantation. METHODS AND RESULTS Since July 1995, 46 patients with a mean age of 45+/-11 years underwent implantation of an electrically drive...
متن کاملImprovement of Left Ventricular Assist Device (LVAD) in Artificial Heart Using Particle Swarm Optimization
In this approach, the Left ventricular assist pump for patients with left ventricular failure isused. The failure of the left ventricle is the most common heart disease during these days. Inthis article, a State feedback controller method is used to optimize the efficiency of a samplingpump current. Particle Swarm Algorithm, which is a set of rules to update the position andvelocity, is applied...
متن کاملOrthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival.
OBJECTIVES Orthotopic heart transplantation is the standard of care for end-stage heart disease. Left ventricular assist device implantation offers an alternative treatment approach. Left ventricular assist device practice has changed dramatically since the 2008 Food and Drug Administration approval of the HeartMate II (Thoratec, Pleasanton, Calif), but at what societal cost? The present study ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- PM & R : the journal of injury, function, and rehabilitation
دوره 3 6 شماره
صفحات -
تاریخ انتشار 2011